Please use this identifier to cite or link to this item: http://elea.unisa.it:8080/xmlui/handle/10556/1377
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRisitano, Antonio M.-
dc.contributor.authorSelleri, Carmine-
dc.date.accessioned2014-06-04T09:43:37Z-
dc.date.available2014-06-04T09:43:37Z-
dc.date.issued2014-
dc.identifier.citationRisitano AM, and Selleri C. Clonal non-malignant hematological disorders: unraveling molecular pathogenic mechanisms to develop novel targeted therapeutics. Translational Medicine @ UniSa 2014;8(1):1-3en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/1377-
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-226-
dc.description.abstractClonal non-malignant hematological disorders are a heterogeneous group of diseases that are particularly challenging for hematologists. Indeed, most obvious and frequent hematological diseases include a broad spectrum of malignancies, such as leukemias, lymphomas, myeloma, and other myeloproliferative or lymphoproliferative disorders. In recent years, all these diseases have been categorized by the WHO according to a novel classification of myeloid and lymphoid malignancies, which takes in account the outstanding progress in our understanding of molecular defects underlying hematological malignancies. Regardless of a number of novel technologies, hematologists continue to deal daily with conditions where a clear diagnosis of a malignancy is missing: this is the case of several clonal hematological disorders, which are considered bona fide non-malignant. Some myelodysplastic syndromes, chronic T and NK disorders of granular lymphocytes, myelofibrosis, monoclonal gammopathies, monoclonal B-cel lymphocytosis, mastocytosis and paroxysmal nocturnal hemoglobinuria are paradigmatic examples of how clonal disorders are clearly different from cancers, even if they may share with hematological malignancies similar molecular, genetic, epigenetic and immunological processes. Indeed, it is not entirely clear whether in individual conditions such pathogenic mechanisms may represent initial step(s) of malignant transformation, making a bridge between these clonal non-malignant disorders and typical hematological cancers. Some of these non-malignant disorders imply specific pathogenic mechanisms and/or clinical course, and so they have been definitely established with their own biological and clinical identity. However, the obvious question whether some of these clonal non-malignant hematological diseases form some a kind of disease-continuum with their corresponding malignant counterpart is still to be answered.en_US
dc.format.extentP. 1-3en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectClonal non-malignant hematological disordersen_US
dc.subjectMDSen_US
dc.subjectChronic T and NK disorders of granular lymphocytesen_US
dc.subjectParoxysmal nocturnal hemoglobinuriaen_US
dc.titleClonal non-malignant hematological disorders: unraveling molecular pathogenic mechanisms to develop novel targeted therapeuticsen_US
dc.typeArticleen_US
Appears in Collections:Translational Medicine @ UniSa. Vol.8 (jan.-mar. 2014)

Files in This Item:
File Description SizeFormat 
Risitano A M, and Selleri C. Clonal non-malignant hematological disorders.pdfarticolo di rivista106,26 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.